Dac590 is an orally Bioavailable FTO Inhibitor with Potent Antileukemia Efficacy. Dac590 exerts a robust antiproliferative effect on AML cells by suppressing oncogenic FTO signaling. Oral administration of Dac590 significantly inhibited xenograft tumor growth and prolonged survival in AML mouse models with no observed toxicity. Notably, Dac590 synergized with decitabine to enhance DNA hypomethylation and further improve the survival rates.
MedKoo Cat#: 129081
Name: Dac590
CAS#: N/A
Chemical Formula: C19H16ClFN2O4
Exact Mass: 390.0783
Molecular Weight: 390.80
Elemental Analysis: C, 58.40; H, 4.13; Cl, 9.07; F, 4.86; N, 7.17; O, 16.38
The following data is based on the product molecular weight 390.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Yang T, Dong Z, Du R, Wang Y, Liu L, Xue Y, Zhang X, Liao Y, Gan J, Yu X, Huang Y, Yang CG. Development of Orally Bioavailable FTO Inhibitors with Potent Antileukemia Efficacy. J Med Chem. 2025 Jun 27. doi: 10.1021/acs.jmedchem.5c00566. Epub ahead of print. PMID: 40579742.
